Pharma BD Deal Intelligence
Sanofi SA / TargeGen, Inc.
2010 · Acquisition/Merger · $560M · Complete
Announcement Sentiment
57
Neutral / mixed
Sanofi-Aventis to acquire TargeGen with $75M upfront + milestones up to $485M (total $560M). Adds JAK2 inhibitor TG101348 for myelofibrosis.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 10yr post-close.
Key facts
- Announced Jun 30, 2010
- Closed Aug 12, 2010
- Deal value $560M
- Deal type Acquisition/Merger
- Therapeutic area Myelofibrosis; myeloproliferative neoplasms
- Indications Myelofibrosis; myeloproliferative neoplasms
- Key assets Fedratinib (TG101348/SAR302503)
- Mechanism JAK2 inhibitor
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals